SCHEMBL1856468

SCHEMBL1856468

COC(=O)c1ccc2cc(OC)ccc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.70
CA1 P00915 2/20 0.68
CA2 P00918 2/20 0.68
PLAU P00749 3/20 0.60
PLG P00747 1/20 0.60
PLAT P00750 1/20 0.60
CYP11B1 P15538 1/20 0.59
CYP11B2 P19099 1/20 0.59
ALDH1A1 P00352 1/20 0.58
CYP1A2 P05177 1/20 0.58
HPGD P15428 1/20 0.58
CYP2C19 P33261 1/20 0.58
HSD17B10 Q99714 1/20 0.58
PTPN11 Q06124 1/20 0.58
KMT2A Q03164 2/20 0.57
HGFAC Q04756 1/20 0.56
LCK P06239 1/20 0.56
MAPT P10636 3/20 0.54
MEN1 O00255 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL545959 0.96 KDM4E (0.66) KDM4ECA1CA2PLAUPLG
SCHEMBL69025 0.90 PTPN11 (0.68) KDM4ECA1CA2PLAUCYP11B1
SCHEMBL29365729 0.90 PTPN11 (0.68) KDM4ECA1CA2PLAUCYP11B1
SCHEMBL12744132 0.90 KDM4E (0.62) KDM4ECA1CA2PLAUPLG
SCHEMBL7558803 0.90 CA1 (0.65) KDM4ECA1CA2PLAUPLG
SCHEMBL8698483 0.89 KDM4E (0.70) KDM4ECA1CA2PLAUPLG
SCHEMBL8732524 0.88 PTPN11 (0.66) KDM4ECA1CA2PLAUCYP11B1
SCHEMBL4940300 0.87 KDM4E (0.55) KDM4ECA1CA2PLAUPLG
SCHEMBL15897010 0.86 CYP11B1 (0.69) KDM4ECA1CA2PLAUPLG
SCHEMBL30698055 0.86 CA1 (0.65) KDM4ECA1CA2PLAUPLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549598-A4 NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) CORTICAL PTY LTD (AU) 2008-01-23 EP claimed
US-20060106102-A1 Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) Morand, Eric 2006-05-18 US claimed
EP-1549598-A1 NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) Cortical Pty Ltd (AU) 2005-07-06 EP claimed
WO-2003104178-A1 NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) CORTICAL PTY LTD (AU) 2003-12-18 WO claimed
US-20230400770-A1 Resist Underlayer Film Material, Patterning Process, And Method For Forming Resist Underlayer Film SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-12-14 US disclosed
US-20230400770-A1 Resist Underlayer Film Material, Patterning Process, And Method For Forming Resist Underlayer Film SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-12-14 US disclosed
WO-2023238515-A1 COMPOSITION, LIQUID CRYSTAL POLYMER SHEET, LOW DIELECTRIC SUBSTRATE MATERIAL, AND WIRING CIRCUIT BOARD 日東電工株式会社 2023-12-14 WO disclosed
EP-4290309-A1 RESIST UNDERLAYER FILM MATERIAL, PATTERNING PROCESS, AND METHOD FOR FORMING RESIST UNDERLAYER FILM SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-12-13 EP disclosed
US-11674966-B2 Kit and method for measuring measurement target substance in biological sample FUJIFILM CORPORATION (JP) 2023-06-13 US disclosed
CN-115160098-B Oxygen-containing compound deoxidization methylation method 中国科学院兰州化学物理研究所 2023-06-06 CN disclosed
EP-4012500-B1 RESIST UNDERLAYER FILM MATERIAL, PATTERNING PROCESS, AND METHOD FOR FORMING RESIST UNDERLAYER FILM SHINETSU CHEMICAL CO (JP) 2023-03-01 EP disclosed
EP-3923074-B1 RESIST UNDERLAYER FILM MATERIAL, PATTERNING PROCESS, AND METHOD FOR FORMING RESIST UNDERLAYER FILM SHINETSU CHEMICAL CO (JP) 2023-02-22 EP disclosed
US-20060217374-A1 Fused heterocyclic derivates as ppar modulators ELI LILLY AND COMPANY 2006-09-28 US disclosed
US-20060106102-A1 Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) Morand, Eric 2006-05-18 US disclosed
EP-1581521-A1 FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-10-05 EP disclosed
US-6849761-B2 Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2005-02-01 US disclosed
WO-2004063190-A1 FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed
US-20040127570-A1 Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2004-07-01 US disclosed
US-5763641-A Process for the preparation of aromatic methoxycarboxylic acid methyl esters BAYER AKTIENGESELLSCHAFT (DE) 1998-06-09 US disclosed
US-4107329-A Fluorinated compounds as therapeutics IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1978-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11674966-B2 Kit and method for measuring measurement target substance in biological sample KIT, TACR2, TACR1 KDM4E 3800/4885CA1 403/4885CA2 1659/4885
US-20060106102-A1 Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) MIF, ARG1, MSR1 KDM4E 3166/4885CA1 2883/4885CA2 3698/4885
US-20060217374-A1 Fused heterocyclic derivates as ppar modulators PPARG, PPARA, PPARD KDM4E 2214/4885CA1 4871/4885CA2 4436/4885
US-20040127570-A1 Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia INSR, GPR119, INSRR KDM4E 3827/4885CA1 3207/4885CA2 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.